Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461806 | 0.93 | TP53 (0.56) | VCAM1KMT2AMEN1NPBWR1MCHR1 | |
| SCHEMBL5473761 | 0.85 | KMT2A (0.70) | VCAM1KMT2AMEN1NPBWR1MCHR1 | |
| SCHEMBL5479450 | 0.82 | TP53 (0.53) | KMT2AMEN1TP53MAPTPOLB | |
| SCHEMBL25754772 | 0.81 | KMT2A (0.55) | KMT2AMEN1TP53MAPTPOLB | |
| SCHEMBL5466708 | 0.80 | VCAM1 (0.56) | VCAM1KMT2AMEN1NPBWR1MCHR1 | |
| SCHEMBL2985916 | 0.78 | KMT2A (0.71) | VCAM1KMT2AMEN1NPBWR1MCHR1 | |
| SCHEMBL2998796 | 0.77 | KMT2A (0.67) | VCAM1KMT2AMEN1NPBWR1MCHR1 | |
| SCHEMBL5461695 | 0.76 | KMT2A (0.66) | VCAM1KMT2AMEN1NPBWR1MCHR1 | |
| SCHEMBL5478374 | 0.76 | TP53 (0.62) | KMT2AMEN1TP53MAPTPOLB | |
| SCHEMBL5467029 | 0.76 | VCAM1 (0.56) | VCAM1KMT2AMEN1NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | VCAM1 4392/4885KMT2A 1132/4885MEN1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.